HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yugendar R Alugubelli Selected Research

Peptides (Polypeptides)

1/2021A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
7/2020A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yugendar R Alugubelli Research Topics

Disease

12COVID-19
03/2024 - 07/2020
2Distal 2 Myopathy
04/2024 - 09/2023
1Communicable Diseases (Infectious Diseases)
09/2023

Drug/Important Bio-Agent (IBA)

6Proteins (Proteins, Gene)FDA Link
04/2024 - 07/2020
6Antiviral Agents (Antivirals)IBA
04/2024 - 12/2021
6Peptide Hydrolases (Proteases)FDA Link
03/2024 - 07/2020
2EnzymesIBA
10/2022 - 12/2021
2N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
10/2022 - 12/2021
2SARS-CoV-2 3C-like proteinaseIBA
01/2022 - 12/2021
2Peptides (Polypeptides)IBA
01/2021 - 07/2020
1Proteasome Endopeptidase Complex (Proteasome)IBA
04/2024
1nirmatrelvirIBA
04/2024
1snake venom protein C activatorIBA
09/2023
1Cathepsin LIBA
01/2022

Therapy/Procedure

2Therapeutics
03/2024 - 04/2023